Alkermes (ALKS) Net Income towards Common Stockholders (2010 - 2026)
Alkermes (ALKS) posted quarterly Net Income towards Common Stockholders of $524000.0 for Q2 2026, up 100.79% quarter-over-quarter from -$66.5 million in Q1 2026.
Alkermes (ALKS) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Net Income towards Common Stockholders for 17 consecutive years, with $524000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Net Income towards Common Stockholders changed N/A year-over-year to $524000.0; the TTM figure through Jun 2026 stood at -$16.6 million (down 2699.53% YoY), while the FY2025 annual figure was $241.7 million, up 4273.82% from the prior year.
- Net Income towards Common Stockholders climbed to $524000.0 in Q2 2026 per ALKS's latest filing, from -$66.5 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $87.7 million in Q4 2022 and bottomed at -$66.5 million in Q1 2026.
- Historically, Net Income towards Common Stockholders has averaged -$15.3 million across 5 years, with a median of -$30.1 million in 2022.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders sank 1374.79% — and 2025, when it soared 4309.91%.
- Alkermes' Net Income towards Common Stockholders stood at $87.7 million in 2022, then sank by 146.58% to -$40.9 million in 2023, then jumped by 102.74% to $1.1 million in 2024, then jumped by 4309.91% to $49.4 million in 2025, then tumbled by 98.94% to $524000.0 in 2026.
- Business Quant data shows ALKS's Net Income towards Common Stockholders at $524000.0 in Q2 2026, -$66.5 million in Q1 2026, and $49.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.30 Bn | 39.65 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.45 Bn | 29.77 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | 710.19 Mn |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.70 Bn | 11.17 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | Alkermes | 8.11 Bn | 7.46 Bn | 397.90 Mn | 524,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 524,000.00 |
| Mar 31, 2026 | -66.53 Mn |
| Dec 31, 2025 | 49.39 Mn |
| Dec 31, 2024 | 1.12 Mn |
| Sep 30, 2024 | -481,000.00 |
| Jun 30, 2024 | -3.91 Mn |
| Mar 31, 2024 | -2.52 Mn |
| Dec 31, 2023 | -40.86 Mn |
| Sep 30, 2023 | -45.35 Mn |
| Jun 30, 2023 | -42.08 Mn |
| Mar 31, 2023 | -36.52 Mn |
| Dec 31, 2022 | 87.72 Mn |
| Sep 30, 2022 | -63.97 Mn |
| Jun 30, 2022 | -30.14 Mn |
| Mar 31, 2022 | -35.90 Mn |
| Dec 31, 2021 | 125.44 Mn |
| Sep 30, 2021 | -28.99 Mn |
| Jun 30, 2021 | 2.36 Mn |
| Mar 31, 2021 | -22.42 Mn |
| Dec 31, 2020 | -42.64 Mn |